MétaCan
Menu
← Back to cohort
Record W4397041661 · doi:10.1681/asn.20233411s1518c

The Utilization of Gabapentin and Pregabalin for the Treatment of CKD-Associated Pruritus and Other Indications in Manitoba

2023· article· en· W4397041661 on OpenAlexaffabout
Silvia Juliana Leon Mantilla, Reid Whitlock, Oksana Harasemiw, Michelle S. DiNella, Gerald Miciak, Clara Bohm, Paul Komenda, Navdeep Tangri, David Collister, Claudio Rigatto

Bibliographic record

VenueJournal of the American Society of Nephrology · 2023
Typearticle
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsUniversity of ManitobaSeven Oaks General Hospital
Fundersnot available
KeywordsGabapentinPregabalinMedicineInternal medicineAnesthesiaIntensive care medicineAlternative medicinePathology

Abstract

fetched live from OpenAlex

Background: Chronic kidney disease-associated pruritus (CKD-aP) frequently affects patients on dialysis, is associated with reduced quality of life, and was identified as a research priority by patients. Until recently there were no approved treatments for CKD-aP, which was often treated with off-label therapies. Systematic reviews published in 2017-2020 identified GABA (gabapentin, pregabalin) analogues as having evidence for efficacy. This real-world study describes the prescription patterns for GABA over time and their frequency of use for CKD-aP. Methods: Retrospective cohort study using administrative health data from Manitoba, Canada (>1.2 million residents). We included all adults (≥ 18 years) who received an incident prescription for a GABA between January 1st, 2012, and March 31st, 2022. We calculated the yearly prescription rate per new user for each GABA in total and for each of the following indications: neuropathy, seizure, fibromyalgia, restless legs syndrome (RLS), and chronic pain. Finally, we estimated the total and annual percentage of GABA prescribed for CKD-aP in the chronic dialysis population (defined as dialysis for 90 consecutive days with no gaps >15 days between sessions). Results: In the study period, there were 125,881 GABA analogue users (adults aged 18 and over). Gabapentin was more commonly prescribed (85%) than pregabalin (15%). The number of new GABA prescriptions increased from 11,301 in 2012 to 12,031 in 2021. Only 0.7% of these were prescribed to treat CKD-aP. There were 4,028 chronic dialysis patients included. Indications for GABA prescriptions in this group were fibromyalgia (24%), seizures (12%), neuropathic pain (9%), RLS (10%) and CKD-aP (19%). Patients receiving GABA for CKD-aP were mostly men (57%) and were older (mean age 60 vs 56 years) than those in the general population. There was a decrease in the proportion of dialysis patients receiving GABA for CKD-aP from 2017 to 2020 (4% to 2.6%) with an increase in 2021 (4%). Conclusions: GABA are rarely used for CKD-aP (0.7% of all GABA use), despite evidence of efficacy. We speculate that safety concerns may limit GABA use. Further studies of the risks:benefit of GABA analogues in CKD-aP are needed. Funding: Commercial Support - Otsuka Canada Pharmaceutical Inc.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.044
Threshold uncertainty score0.099

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0030.005
Science and technology studies0.0010.001
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.321
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicDermatology and Skin Diseases→French-language works237,207→